We have located links that may give you full text access.
Long-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: 6 years of treatment.
Arthritis Care & Research 2018 October 16
OBJECTIVE: To report long-term health-related quality of life (HRQoL) and fatigue outcomes in patients with systemic lupus erythematosus (SLE) receiving belimumab.
METHODS: Patients with SLE who completed the BLISS-76 trial were enrolled into this continuation study (BEL112233, NCT00724867). The belimumab groups continued to receive the same dose (1 mg/kg or 10 mg/kg intravenously; post-March 2011 all patients received 10 mg/kg) every 28 days, plus standard of care (SoC). The placebo group switched to belimumab 10 mg/kg. HRQoL and fatigue assessments included the Short Form-36 (SF-36) Health Survey and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale. Post hoc subgroup analyses (BEL206350) assessed clinical characteristics associated with improved HRQoL and fatigue.
RESULTS: 268 patients enrolled; 140 completed the study. Patients receiving long-term belimumab reported continued improvements in HRQoL and fatigue. At Study Year 6, mean (standard deviation [SD]) Physical Component Summary (PCS) and Mental Component Summary (MCS) SF-36 scores increased from baseline 37.0 (9.9) to 41.7 (10.0; mean change, 4.8 [9.4]) for PCS and from 44.3 (11.3) to 47.0 (11.6; mean change, 2.7 [11.3]) for MCS, exceeding the minimum clinically important difference (MCID) for improvement (2.5 units). Mean (SD) FACIT-Fatigue score exceeded the MCID of 4 at Study Years 1-5; at Study Year 6 the mean change was 3.7 (11.8). Statistically significant associations were observed between parent trial treatment groups and change from baseline in PCS, MCS, and FACIT-Fatigue scores (p<0.01).
CONCLUSION: Long-term control of disease activity with belimumab plus SoC translates into meaningful improvements in patient-reported fatigue and HRQoL.
METHODS: Patients with SLE who completed the BLISS-76 trial were enrolled into this continuation study (BEL112233, NCT00724867). The belimumab groups continued to receive the same dose (1 mg/kg or 10 mg/kg intravenously; post-March 2011 all patients received 10 mg/kg) every 28 days, plus standard of care (SoC). The placebo group switched to belimumab 10 mg/kg. HRQoL and fatigue assessments included the Short Form-36 (SF-36) Health Survey and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale. Post hoc subgroup analyses (BEL206350) assessed clinical characteristics associated with improved HRQoL and fatigue.
RESULTS: 268 patients enrolled; 140 completed the study. Patients receiving long-term belimumab reported continued improvements in HRQoL and fatigue. At Study Year 6, mean (standard deviation [SD]) Physical Component Summary (PCS) and Mental Component Summary (MCS) SF-36 scores increased from baseline 37.0 (9.9) to 41.7 (10.0; mean change, 4.8 [9.4]) for PCS and from 44.3 (11.3) to 47.0 (11.6; mean change, 2.7 [11.3]) for MCS, exceeding the minimum clinically important difference (MCID) for improvement (2.5 units). Mean (SD) FACIT-Fatigue score exceeded the MCID of 4 at Study Years 1-5; at Study Year 6 the mean change was 3.7 (11.8). Statistically significant associations were observed between parent trial treatment groups and change from baseline in PCS, MCS, and FACIT-Fatigue scores (p<0.01).
CONCLUSION: Long-term control of disease activity with belimumab plus SoC translates into meaningful improvements in patient-reported fatigue and HRQoL.
Full text links
Related Resources
Trending Papers
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Review article: Recent advances in ascites and acute kidney injury management in cirrhosis.Alimentary Pharmacology & Therapeutics 2024 March 26
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app